TAM
ABBV icon

Trillium Asset Management’s AbbVie ABBV Stock Holding History

Trillium Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$715K Sell
2,843
-10
-0.4% -$2.15K 0.02% 176
2026
Q1 		$620K Buy
2,853
+186
+7% +$41.3K 0.02% 178
2025
Q4 		$609K Hold
2,667
– – 0.02% 178
2025
Q3 		$618K Sell
2,667
-15
-0.6% -$3.06K 0.02% 178
2025
Q2 		$498K Buy
2,682
+23
+0.9% +$4.28K 0.01% 185
2025
Q1 		$557K Hold
2,659
– – 0.02% 181
2024
Q4 		$473K Buy
2,659
+71
+3% +$13.1K 0.01% 189
2024
Q3 		$511K Sell
2,588
-175
-6% -$32.7K 0.01% 194
2024
Q2 		$474K Hold
2,763
– – 0.01% 198
2024
Q1 		$503K Sell
2,763
-285
-9% -$49.1K 0.01% 198
2023
Q4 		$472K Sell
3,048
-346
-10% -$50.4K 0.01% 197
2023
Q3 		$506K Sell
3,394
-1,552
-31% -$228K 0.02% 191
2023
Q2 		$666K Sell
4,946
-115
-2% -$16.9K 0.02% 177
2023
Q1 		$765K Buy
5,061
+75
+2% +$11.5K 0.02% 173
2022
Q4 		$806K Hold
4,986
– – 0.02% 178
2022
Q3 		$669K Hold
4,986
– – 0.02% 174
2022
Q2 		$764K Sell
4,986
-4,075
-45% -$623K 0.02% 176
2022
Q1 		$1.47M Buy
9,061
+180
+2% +$26.1K 0.04% 170
2021
Q4 		$1.2M Buy
8,881
+1,608
+22% +$190K 0.03% 181
2021
Q3 		$785K Buy
7,273
+610
+9% +$69.7K 0.02% 187
2021
Q2 		$751K Sell
6,663
-99
-1% -$11.2K 0.02% 186
2021
Q1 		$732K Hold
6,762
– – 0.02% 183
2020
Q4 		$725K Sell
6,762
-2,434
-26% -$234K 0.03% 188
2020
Q3 		$805K Buy
9,196
+1,903
+26% +$179K 0.03% 170
2020
Q2 		$716K Buy
+7,293
New +$642K 0.03% 180
2019
Q4 		– Sell
-4,201
Closed -$318K – 259
2019
Q3 		$318K Buy
+4,201
New +$288K 0.01% 227

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Trillium Asset Management's ABBV Position: Q2 2026 in Review

Trillium Asset Management reduced its AbbVie (ABBV) stake by 0.35% in Q2 2026, selling an estimated $2.15K and leaving 2,843 shares worth $715K. The position accounts for 0.02% of the portfolio, ranked #176.

Trillium Asset Management first reported a position in ABBV in Q3 2019 and has held it in 26 quarters since. The position peaked at $1.47M in Q1 2022. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Trillium Asset Management held 2,843 shares of AbbVie worth $715K as of Q2 2026.
  • Trillium Asset Management sold 10 AbbVie shares in Q2 2026, an estimated $2.15K.
  • AbbVie made up 0.02% of Trillium Asset Management's portfolio in Q2 2026, its #176 holding.
  • Trillium Asset Management first reported a position in AbbVie in Q3 2019 and has held it in 26 quarters since.
  • Trillium Asset Management's AbbVie position peaked at $1.47M in Q1 2022.
  • 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Trillium Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.